Centene Corporation (CNC) Down 11.8% — Cut It Loose?
Centene Corporation (CNC) was under heavy pressure in the latest session, with the stock sliding 11.8% and losing $5.46 to close at $40.82. The move marks a sharp retreat from the prior close of $46.28 and extends a pattern of the shares losing ground after previously testing much higher levels this year. Trading activity reached 4.8 million shares, coming in well below the 90-day average volume of about 8.6 million, suggesting that this steep decline unfolded without a surge in participation from the broader market. Even with lighter-than-normal volume, the size of the one-day drop stands out and keeps the near-term price trend tilted firmly to the downside.
From a longer-term perspective, the stock has pulled back significantly from its 52-week high of $66.81 set on Feb. 3, 2025, leaving it trading roughly 39% below that peak. This places Centene firmly in the lower half of its annual range and underscores the extent to which the share price has been retreating over recent months. Within the broader health-related cohort, several sector peers such as Humana (HUM) and Molina Healthcare (MOH) have also seen bouts of weakness at various points, but the magnitude of Centene’s latest single-day decline stands out as particularly severe. Overall, the recent action shows a stock under pressure, struggling to regain lost ground and facing ongoing headwinds as it moves further away from prior highs.
Why Centene Corporation Price is Moving Lower
Centene Corporation’s share price is sliding under a confluence of company-specific headwinds that have shaken investor confidence. The most immediate pressure stems from the sharp reset in its Marketplace and Medicaid businesses, which forced management to withdraw 2025 financial guidance and acknowledge a $1.8 billion cut in risk adjustment revenue, translating to roughly a $2.75 EPS hit. That kind of guidance withdrawal is typically seen as a serious red flag, raising concerns over visibility, pricing discipline and underwriting accuracy in key lines of business. The stock’s recent plunge to a 52-week low of $27.33, alongside a roughly 59% decline over the past year, reflects mounting skepticism that the current business mix can deliver stable, predictable earnings.
Fundamentally, the top line is still growing – revenue rose to $44.58 billion in the latest quarter, up 6.8% sequentially and 21.48% year over year. However, that growth is coming with deteriorating economics, as evidenced by a negative profit margin of -3.15% and deeply negative trailing EPS. In a managed care and health services environment already pressured by regulatory scrutiny and reimbursement risk, investors are giving less credit for revenue scale and more weight to profit volatility. The upcoming Q4 2025 earnings call on Feb. 6, 2026, with a notably weak EPS estimate, is another overhang, keeping traders cautious ahead of potential additional revisions. Sector peers such as Humana, Molina Healthcare, Baxter and others in Health Care Equipment and Services have also faced regulatory and cost pressures, but Centene’s magnitude of guidance disruption and earnings risk has left its stock under disproportionate pressure.
What is the Centene Corporation Rating - Should I Sell?
Weiss Ratings assigns CNC a D rating. Current recommendation is Sell. This rating was downgraded on 7/25/2025, signaling rising concern about the stock’s risk/reward profile. A D rating indicates that, in our view, Centene has underperformed relative to other stocks with comparable risk and does not offer a compelling case for new capital or continued exposure.
The underlying sub-indices help explain why. Centene carries a Weak Growth Index and a Weak Efficiency Index, despite reporting revenue growth of 21.48%. That top-line expansion has not translated into healthy profitability or shareholder value. The company’s profit margin of -3.15% and a negative forward P/E of -4.27 point to ongoing earnings pressures. In other words, fast-growing revenue has come with too much cost, dilution, or operational drag to benefit investors meaningfully.
On the risk side, Centene’s Excellent Solvency Index indicates a solid balance sheet and an ability to meet financial obligations, but this strength is outweighed by a Weak Volatility Index and a Weak Total Return Index. Historically poor, risk-adjusted returns and choppy trading behavior have penalized shareholders, even as the company remains financially stable on paper. The overall D rating reflects that this combination has not protected investors from downside.
Within the Health Care group, Centene’s D rating puts it alongside names such as Humana Inc. (HUM, D+), Molina Healthcare, Inc. (MOH, D+), and Baxter International Inc. (BAX, D). While the peer set is generally challenged, Centene’s persistent earnings and return issues, coupled with its downgrade and weak sub-indices, argue for heightened caution.
About Centene Corporation
Centene Corporation is a managed care provider focused on government-sponsored and commercial healthcare plans in the United States, with a core emphasis on under-insured and uninsured populations. Operating through four primary segments — Medicaid, Medicare, Commercial, and Other — the company embeds itself deeply into public health programs where regulatory complexity and administrative burden are high. Its Medicaid segment administers a wide range of programs including Temporary Assistance for Needy Families, Medicaid expansion, aged, blind, or disabled coverage, Children’s Health Insurance Program (CHIP), long-term services and supports, foster care, and Medicare-Medicaid integrated plans. This structure positions Centene as a large-scale intermediary between government payors and care providers, but also concentrates its business in heavily regulated, politically sensitive funding streams.
In Medicare, Centene offers Medicare Advantage special needs plans, Medicare supplement products, and standalone prescription drug plans, targeting beneficiaries who often require higher-touch care management. The Commercial segment sells health insurance marketplace products to individuals and to small and large employer groups, competing in a crowded field of national and regional health plans. Through its Other segment, Centene runs clinical healthcare operations and pharmacies, and provides vision, dental, behavioral health, federal services, and corporate management functions. Services are delivered via contracted networks of primary care and specialty physicians, hospitals, behavioral health practitioners, and ancillary providers. This reliance on third-party networks, combined with the company’s broad exposure to government reimbursement and complex benefit designs, leaves Centene facing ongoing operational challenges in cost control, care coordination, and compliance.
Investor Outlook
With Centene Corporation (CNC) carrying a D (Sell) Weiss Rating, investors may want to exercise caution and closely monitor whether recent price weakness stabilizes or accelerates. Watch for shifts in health care policy, reimbursement trends, and any signs of improving profitability or cash flow that could eventually support a rating upgrade. See full rankings of all D-rated Health Care stocks inside the Weiss Stock Screener.
--